AzurRx (AZRX) Corporate Media Kit

11 Phase 2 MS1819 Clinical Trials MS1819 Doses # Patients Safety Primary Efficacy Endpoint Results Secondary Efficacy Endpoints Results Status CP patients Dose Escalation • 280 mg • 560 mg • 1120 mg • 2240mg 11 France, Aus, NZ • Statistically significant 21.8% CFA improvement at highest dose of 2.2 g Statistically Significant and Clinically Meaningful • # bowel movements • stool consistency • steatorrhea Completed 2018 CF patients Bridging Dose Safety • 2240 mg 32 U.S., Poland • CFA: MS1819 56% vs. PERT 86% • ~50% of patients reached non- inferiority • CNA: MS1819 93% vs. PERT 97% - no need for protease Completed 2019 CF patients Dose Escalation • 2240 mg + Enteric Capsule • 4480 mg + Enteric Capsule 30* U.S., Poland Initiated Q3 2020 Topline Data Q1 2021* CF patients Dose Escalation Daily Dose PERT + • 700 mg • 1120 mg • 2240 mg 20* Hungary, Spain, Turkey • Positive CFA Data on 1 st five patients in study • Clinically Meaningful Data on 1 st five patients in study Initiated Q4 2019 Topline Data Q2 2021* * Anticipated MS1819 Clinical Trials Established Safety, Primary and Secondary Endpoint Efficacy, No Need for Protease